Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Central & Western Europe

Central & Western Europe

In Central & Western Europe, the revenue in the Neoplasm Treatment market is projected to reach US$48.47bn in 2024.
It is expected to show an annual growth rate of 4.55% from 2024 to 2029, resulting in a market volume of US$60.54bn by 2029.
When compared globally, United States is forecasted to generate the highest revenue, amounting to US$90.56bn in 2024.
In Central & Western Europe, Germany has emerged as a leading hub for neoplasm treatment, with its state-of-the-art facilities and cutting-edge research.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.